In-house r&d services

BIGLYCAN THERAPY

Biglycan™ therapy: open for out-licensing and/or co-development partnership

biglyan

Use of biglycan or enhancers of biglycan activity in the preparation of pharmaceutical compositions

Scientific background:

  • Overexpression of biglycan is anti-atherosclerotic and induces cardioprotective genes: eNOS, nNOS, iNOS, Pyk2 in the mice heart in vivo (Bereczki et al, J Proteome Res, 2007).
  • Exogenuos bigycan protects cardiac myocytes from hypoxia and reoxygenation, and overexpression of biglycan reduces infarct size (Csont et al, J Mol Cell Cardiol, 2010).

Summary of invention:

The present invention relates to the use of biglycan or enhancers of biglycan activity in the preparation of pharmaceutical compositions having anti-atherosclerotic and  anti-ischemic effects, and to the use thereof in methods for preventing and treating the atherosclerotic and ischemic (e.g. cardiac) diseases. The invention also relates to screening methods by which biglycan or enhancers of biglycan activity can be identified.

IP status:

  • Patented technology (primary filing date Jan 2007, WO_2008/084268_A1), currently in national phase in India, granted in EU, China
  • biglycan and glycantherapy are trademarks of Pharmahungary, please see www.biglycan.com

Planned project duration:

  • 36 months (up to phase I clinical trial)

Potential investors and/or co-development partners, please contact us for further details at businessdevelopment@pharmahungary.com.

MMP INHIBITORS

MMP inhibitors project: open for out-licensing or co-development partnership

mmp

Scientific background:

  • MMP-s are involved in acute ischemia/reperfusion injury. Inhibition of MMP-2 is able to reduce ishcemia/reperfusion injury, e.g. it can reduce infarct size (Giricz et al, J Pharm Exp Ther, 316:154-161, 2006)
  • Short term application of selective MMP inhibitors for acute diseases, e.g. acute myocardial infarction have better safety profile than previous clinical stage non-selective MMP inhibitors (Dormán et al, Drugs 70:949-964, 2010; Recent Patents Dormán et al, Cardiovasc Drug Discov 2:186-194, 2007)

Summary of invention:

  • Novel chemical entities (small molecules) for selective inhibition of MMP 2, 9, 13, and their application for ischemic (e.g. heart) diseases, or any other diseases where pathological increase in MMP activation is involved in the pathology.

IP status:

  • Patented technology (primary filing date Dec, 2010, WO_2012/080762_A1)
  • Currently in national phases worldwide, granted in USA, China

Planned project duration:

  •  36 months (up to IND)

If you are interested in our project as an investor or co-development partner, please contact us for further details at businessdevelopment@pharmahungary.com.

ProtectomiR

ProtectomiR project: open for out-licensing and/or co-development partnership

mirna

Summary of invention:

Several miRNA compounds for cytoprotection in ischemic diseases, method of identification for cytoprotective miRNA targets, termed “protectomiRs”.

IP status:

  • Patented technology (primary filing date Oct,  2011, WO_2013/057527_A2)
  • Currently in national phases China, EU, granted in USA
  • protectomiR, pathomiR, therapomiR, toxicomiR, and diagnomiR are trademarks of Pharmahungary, see www.protectomir.com

If you are interested in our project as an investor or co-development partner, please contact us for further details at businessdevelopment@pharmahungary.com.